【摘 要】
:
Anthracycline-based chemotherapy is commonly used in the adjuvant or neoadjuvant setting of breast cancer.Topoisomerase ⅡA has been suggested as a possible predictive factor of response to anthracycli
【机 构】
:
Department of Surgery and Breast Surgery National Hospital Organization Kure Medical Center and Chug
【出 处】
:
(BITs 3rd Annual World Cancer Congress-2010, Breast Cancer C
论文部分内容阅读
Anthracycline-based chemotherapy is commonly used in the adjuvant or neoadjuvant setting of breast cancer.Topoisomerase ⅡA has been suggested as a possible predictive factor of response to anthracyclines.Ki-67 is frequently measured to estimate the proliferative activity of tumor cells, and potentially could be a predictor of chemotherapeutic efficacy.We analyzed the relationship between the expression of topoisomerase ⅡA and Ki-67 in the breast cancer and its regression as induced by neoadjuvant chemotherapy, and examined if topoisomerase ⅡA and Ki-67 were associative predictors of the response.Methods: From May 2005 until January 2009, 38 patients who underwent neoadjuvant chemotherapy were examined.Prior to chemotherapy, we had obtained specimens by core needle biopsy,and measured the expression of topoisomerase ⅡA protein and Ki-67 with immunohistochemical staining, and determined the gene copy number of topoisomerase ⅡA by fluorescence in situ hybridization.We measured the sizes of tumors (maximum length+vertical length) with images of MRI and CT before and after the chemotherapy, and subsequently calculated the reduction rate of the tumors.Results: Topoisomerase ⅡA expression significantly correlated with the expression of Ki-67 in breast cancer (r2=0.5107, p<0.01).In the cohort of high expression of topoisomerase ⅡA protein (topoisomerase ⅡA≥25%), the reduction rate was significantly higher than that observed in the cohort of lower expression of topoisomerase ⅡA protein (topoisomerase ⅡA<10%).There was an association between Ki-67 and the reduction rate, but it was not statistically significant.There was no association between the gene copy number of topoisomerase ⅡA and reduction rate.Conclusion: Topoisomerase ⅡA protein overexpression can predict benefits of treatment with an thracyclines in the neoadjuvant setting of breast cancer.
其他文献
There is an urgent need for cost-effective, noninvasive diagnostic techniques for the evaluation of breast lesions.While contrast-enhanced magnetic resonance imaging (MRI) now provide very high sensit
Purpose: Breast cancer is the most common female malignancy in Taiwan; quality of life following breast cancer therapy, though, remains rarely addressed.The aim is to evaluate quality of life among Ta
IGF-1 is essential for normal mammary gland development but also associated with premenopausal breast cancer risk.Combined oral contraceptives (OCs) decrease the IGF-1 levels in most women.The endogen
[Purpose] Endocrine ductal carcinoma in situ (E-DCIS) is an intraductal carcinoma characterized by endocrine features and expression of neuroendocrine markers.E-DCIS and intraductal papilloma (IDP) re
Histologic grade is a well-established prognostic factor for breast cancer.Many trials and studies had proven its role and significance in Caucasian women.However, the relationships among histologic g
Background: Breast carcinoma is the commonest cancer among Singaporean women.Syndecan-1 is a transmembrane heparan sulphate proteoglycan.Previous studies have shown that heparan sulphate is overexpres
Spontaneous canine inflammatory mammary cancer (IMC) shares epidemiologic, histopathological and clinical characteristics with the disease in humans and thereby it has proposed as a natural model for
Objective: Breast carcinoma classification has dramatically changed in recent years following application of molecular techniques.Immunohistochemistry can help select patients for diferent therapies.T
OBJETIVE: To investigate the prognostic value of the expression of cyclins D1 and D2, bcl2 and COX-2 on the outcome of very young breast cancer patients (below 35 years), and other clinicopathologic p
Introduction: The axillary lymph node status is a powerful predictor of overall survival in patients with breast cancer.The sentinel lymph node is the first node to receive lymphatic drainage.The comb